A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy,
safety, and tolerability of MORF-057 in adult patients with Moderate to Severe Ulcerative
Colitis (UC)